

**Anti-Infective Drugs Advisory Committee Meeting  
June 3, 2009**

Developing new drugs for the treatment of tuberculosis  
Hilton/Silver Spring, Maryland

---

Meeting Roster

**ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

Thomas Moore, M.D., FACP (Chair)

Clinical Professor  
Department of Medicine  
University of Kansas School of Medicine  
Wichita, KS

W. Kemper Alston, M.D., M.P.H.

Professor of Medicine  
Infectious Diseases Unit  
Fletcher Allen Health Care  
University of Vermont College of Medicine  
Burlington, VT

Archana Chatterjee, M.D., Ph.D.

Professor of Pediatrics  
Chief, Pediatric Infectious Diseases Division  
Creighton University School of Medicine  
Omaha, NE

Dean Follmann, Ph.D.

Assistant Director for Biostatistics  
National Institute of Allergy and Infectious Diseases  
Bethesda, MD

Matthew Bidwell Goetz, M.D.

Professor of Clinical Medicine  
David Geffen School of Medicine at UCLA  
Chief, Infectious Diseases Section  
VA Greater Los Angeles Healthcare System  
Los Angeles, CA

Sheldon Kaplan, M.D.

Professor and Vice-Chairman for Clinical Affairs  
Head, Section of Pediatric Infectious Diseases  
Department of Pediatrics  
Baylor College of Medicine  
Chief, Infectious Disease Service  
Texas Children's Hospital  
Houston, TX

Peter Katona, M.D.

Associate Professor of Clinical Medicine  
David Geffen School of Medicine at UCLA  
Los Angeles, CA

Carol Kauffman, M.D.

Professor, Infectious Diseases Section  
Veterans Affairs Healthcare System  
Ann Arbor, MI

Kent Sepkowitz, M.D.

Vice Chairman, Clinical Affairs  
Director, Hospital Infection Control  
Memorial Sloan-Kettering Cancer Center  
New York, NY

Margo Smith, M.D.

Director, Infectious Diseases  
Washington Hospital Center  
Washington, D.C.

Annie Wong-Beringer, Pharm.D.

Associate Professor of Pharmacy  
University of Southern California  
School of Pharmacy  
Los Angeles, CA

**INDUSTRY REPRESENTATIVE (Non-Voting)**

John H. Rex, M.D., F.A.C.P.

Infection Clinical Vice President  
AstraZeneca; Alderley House  
United Kingdom

**Anti-Infective Drugs Advisory Committee Meeting  
June 3, 2009**

Developing new drugs for the treatment of tuberculosis  
Hilton/Silver Spring, Maryland

**TEMPORARY VOTING MEMBERS (Voting)**

Jo-Ellen De Luca (Patient Representative)  
Spartanburg, SC 29302

Ralph B. D'Agostino, Ph.D.  
Professor of Mathematics/Statistics  
and Public Health  
Boston University  
Boston, MA

Fred M. Gordin, M.D.  
Chief, Infectious Diseases  
Veterans Affairs Medical Center  
Professor of Medicine  
The George Washington University  
Washington DC

Carol D. Hamilton, M.D, M.HS, FIDSA, FACP  
Professor of Medicine, Consulting, Duke University  
Senior Director, Research  
Family Health International  
Research Triangle Park, North Carolina

Petros C. Karakousis, M.D.  
Assistant Professor of Medicine and International  
Health  
Center for Tuberculosis Research  
Johns Hopkins University School of Medicine  
Baltimore, MD

Darren R. Linkin, M.D., M.S.C.E.  
Assistant Professor  
Department of Medicine, Division of Infectious  
Diseases  
Department of Biostatistics and Epidemiology  
University of Pennsylvania  
Philadelphia, PA

Sharon Nachman M.D.  
Professor Pediatrics  
Associate Dean for Research  
SUNY Stony Brook

Frank G. Witebsky, M.D.  
Assistant Chief, Microbiology Service  
Department of Laboratory Medicine  
Warren G. Magnuson Clinical Center  
National Institutes of Health  
Bethesda, Maryland

**FDA PARTICIPANTS (Non-Voting)**

Edward Cox, M.D., M.P.H.  
Director, Office of Antimicrobial Products (OAP)

Renata Albrecht, M.D.  
Director, Division of Special Pathogen and Transplant Products (DSPTP)

Joette Meyer, Pharm.D.  
Clinical Team Leader, DSPTP

Tafadzwa Vargas-Kasambira, M.D., M.P.H.  
Medical Officer, DSPTP